DIAGNOSTIC VALUE OF STIMULATED SERUM THYROGLOBULIN IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER
Vlado Wagenhofer, Ivan Mihaljević, Tatjana Kralj, Dubravka Vrdoljak, Tomislav Kizivat · 2024
Read DIAGNOSTIC VALUE OF STIMULATED SERUM THYROGLOBULIN IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER by Vlado Wagenhofer, Ivan Mihaljević, Tatjana Kralj, Dubravka Vrdoljak, Tomislav Kizivat (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12490462.txt.
Description
Vlado Wagenhofer and co-authors test a follow-up blood marker for thyroid cancer in a 2024 study. After treatment for differentiated thyroid cancer, doctors watch for leftover or returning disease. A protein called thyroglobulin, made only by thyroid tissue, serves as the alarm: they measure it while stimulating the gland remnant. A negative first test is reassuring, but whether yearly repeats add value was open.
The team reviewed three hundred eighty-eight patients treated and followed at a university hospital in Osijek between 2004 and 2018. In low-risk patients, a negative first stimulated test almost never missed disease. In the middle-risk group it was nearly as strong. Comparing one test with three annual rounds shows how little the repeats add when the first is clean. That matters for sparing patients needless stimulation tests.
Catalog record
| CREATOR | Vlado Wagenhofer, Ivan Mihaljević, Tatjana Kralj, Dubravka Vrdoljak, Tomislav Kizivat |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |